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Abstract: Dupuytren’s disease is one of the most common condition seen by hand surgeons. It is not only prevalent but 
can also be a most debilitating condition resulting in significant loss of function of the fingers involved. The cause of this 
disease, however still remains largely unknown although some recent evidence suggests a stem cell etiology. This review 
article summarizes the current known knowledge of Dupuytren’s as well as the clinical findings, investigations and 
treatments available. 
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  Dupuytren's disease is a fibroproliferative condition of 
the palmar fascia and results in thickening and shortening of 
the normal fibrous bands in the hand and fingers. Although 
benign, the disease can cause disabling, progressive digital 
contractures. 
  The earliest published description of the disorder was in 
1614 by Felix Platter [1], but it was Guillian Dupuytren who 
presented a meticulous anatomic and pathological study in 
1831[2]. What was unique about Dupuytren’s description 
was that he emphasized the clinical course of the disease and 
described the procedure of fasciotomy for its treatment. 
EPIDEMIOLOGY 
  The reported prevalence of Dupuytren's disease varies 
from 2% to 42%. This wide variety is influenced mainly by 
ethnicity, gender and age [3, 4]. The highest prevalence is 
observed in Scandinavia, Great Britain, Ireland, Australia 
and North American populations [5-7]. Men are more 
commonly affected by the disease with a male: female ratio 
ranging between 3.5:1 and 9:1 [8, 9]. The incidence rises 
sharply after the fourth and fifth decade, with men and 
women being affected by the same frequency after the age of 
80 years [3].The incidence of Dupuytren’s disease increases 
with concurrent disorders and behavioral factors such as 
diabetes, alcoholism, smoking, HIV infection and 
hyperlipideamia [10-12]. The effect of convulsive disorders 
on the incidence of the disease is yet to be established [13, 
14]. 
ETIOLOGY 
  The cause of Dupuytren’s disease remains unclear 
despite the advanced understanding of the disease in the last  
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decade. Dupuytren suggested that the disease was caused by 
local trauma [15]. Although some studies have supported 
this relationship others have failed to confirm this [16]. 
Some have implicated a genetic predisposition to the disease 
[4, 17-19]. An autosomal dominant inheritance pattern with 
variable penetrance has been suggested [4] as well as more 
complex traits [19]. The correlation between Dupuytren's 
disease and occupation, mainly vibration and manual work, 
is still debatable [20-22]. Other etiologic mechanisms that 
have been implicated include free radicals [23], autoimmune 
[24] and neoplasia [25]. 
PATHOPHYSIOLOGY 
  The pathological nodules and cords in Dupuytren's 
disease are the result of a fibroproliferative disorder of the 
palmar aponeurosis. Hystologically the disease progresses 
through three different phases namely; Proliferative, 
involution and residual phases [25]. 
  The proliferative stage is characterized by fascial 
ﬁbroplasia, nodule formation and proliferation of fibroblasts. 
It is believed that uncontrolled fibroblast proliferation is 
responsible for the nodule formation. Under the influence of 
local mediators such as transforming growth factor - TGF-
1, and the recently suggested periostin [26] the cells can be 
induced to transform to myofibroblasts [27]. The control of 
myofibroblast transformation within the Dupuytren tissue 
shares common features with that observed in the process of 
granulation and wound healing [28]. 
  During the subsequent involution phase rearrangement of 
the cells along the stress lines of the tissue occurs. 
Macroscopically cords begin to develop. The myofibroblasts 
are the predominant cells in this phase. They have 
morphological features of fibroblasts and smooth muscle 
cells [29] and have the ability of synthesizing collagen and 
alpha-smooth muscle actin which plays a role in contraction 
[29, 30]. The excessive collagen production leads to nodules 
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fraction of collagen type III [31, 32], and the resultant 
deposits. The abnormal collagen cross-linkage and the 
continuous contraction of the myofibroblasts result in the 
subsequent contractures. 
  In the residual phase the nodules regress leaving thick 
cords and a relatively acellular residual tissue. The cords 
become visible, and the contractures severe. 
  Other growth factors have been found with increased 
expression within the diseased tissue, these include fibroblast 
growth factor and platelet-driven growth factor [33]. In their 
recent study Forsman et al. demonstrated a decrease in 
expressed myoglobin, and an increase in tyrosine kinase – 
like orphan receptor. The later protein is associated with 
other diseases of the hand [34]. Metalloproteinase act to 
mediate regulation of the tensile strength of the abnormal 
fibroblasts in Dupuytren's disease, this activity seems to have 
an additional role in the development of Dupuytren’s 
changes [35, 36]. 
PATHOANATOMY 
  Dupuytren’s disease affects the palmar fascial complex, 
the disease cords originate from the normal fascial bands 
within the palm and digits [37]. Palmar cords result in 
metacarpophalangeal contractures whereas digital cords 
result in proximal interphalangeal contractures. 
 Palmar  cords  are the most common cords and include: 
 Peritendinous  cords are the most common among the 
palmar cords. They originate from the peritendinous fascial 
band and can be continuous with the digital cords [38] or 
may bifurcate distally to different digits. These cords usually 
do not displace the neurovascular bundle [39]. They arise 
from the peritendinous bands, which are the extension of the 
longitudinal fibers of the central aponeurosis in the digits II-
IV and of the radial and ulnar aponeurosis in the thumb and 
small finger respectively. Each peritendinous band bifurcates 
distally and forms three layers: superficial, middle and deep 
[39]. The middle layer passes to the digit as the spiral band 
 Natatory  cords  originate from the natatory ligaments 
and cause contractures of the second through to the fourth 
web space. These contractures result in constriction of 
fingers abduction. The distal natatory ligaments are found in 
the second to fourth web space at the palmar digital junction 
and acts to connect the adjacent web skin [40]. 
 Vertical  cords  arise from the vertical fibers. These fibers 
include small superficial fibers that connect the superficial 
palmar aponeurosis to the skin, known as Grapow fibers 
[36], and the septa of Legueu and Juvara, Vertical bands are 
relatively uncommon. 
 Digital  cords: Are responsible for the contractures in the 
interphalangeal joints. 
 Central  cords are the most common among the digital 
cords. They lie between the neurovascular bundles and 
continue the Peritendonious cord into the digit. Distally the 
central cord is attached to the flexor tendon and the 
periosteum of the middle phalanx. Neurovascular 
displacement due to a central cord is rare. 
  The spiral cord is the result of pathological blending of 
the peritendinous band, spiral band, lateral digital band and 
the Grayson's ligament [41]. Distal to the bifurcation of the 
peritendinous bands the fibers of the middle layer on each 
side form the spiral band [42]. They run dorsal to the 
neurovascular bundles and blends distally with lateral digital 
band fibers. Grayson´s ligaments are composed of the fibers 
passing volarly to the neurovascular bundle and attach the 
lateral digital band to the joint capsule, tendon sheath and the 
periosteum. The course of the spiral cord around the 
neurovascular bundle causes multidirectional displacement 
and thus makes the bundle susceptible to surgical injury [36, 
43]. The spiral cord usually causes a severe proximal 
interphalangeal joint contracture. 
  The lateral digital cord is the result of pathological 
changes in the lateral digital sheet. The cord causes a 
proximal interphalangeal contracture and may involve the 
distal interphalangeal joint as well through Grayson’s 
ligament. The lateral cords may cause a medial displacement 
of the neurovascular bundle. 
  Within the digits, duplication's disease usually does not 
involve the Cleland ligament, the oblique retinacular 
ligaments, and other deeper fascial layers [44, 45] 
 Ulnar  cords:  The ulnar border of the palm is a common 
site of involvement in Dupuytren’s disease. The abductor 
digiti minimi cord arises from the abductor digiti mini 
muscle or tendon and inserts in the base of the middle 
phalanx. It runs in the ulnar side of the proximal phalanx and 
superficial to neurovascular bundle. This cord is not well 
defined and its origin and course varies frequently. It may 
inserts distally in the distal phalanx causing a distal 
interphalangeal contracture. 
 Radial  cords: The radial aponeurosis is composed of the 
two commissural ligaments, the extension of the central 
palmar aponeurosis known as the thenar fascia and the 
peritendinous band of the thumb [40]. The distal 
commissural cord is the radial equivalent of the natatory 
cord in the first web space. It arises from the distal 
commissural ligament and is responsible  for the first 
abduction contracture. 
  The proximal commissural cord results from a diseased 
proximal commissural ligament. The ligament is the radial 
extension of the superficial transverse fibers of the palmar 
aponeurosis. 
  The thenar cord is a result of thickening of the thenar 
fascia. It inserts in the radial aspect of the first 
metacarpophalngeal joint. 
CLINICAL PRESENTATION 
  A detailed patient history and a careful physical 
examination are mandatory and sufficient for making the 
diagnosis without the need of additional studies [46]. The 
small and the ring fingers are most commonly affected in the 
disease [3] with bilateral involvement in the majority of the 
cases. Palmar skin symptoms occur early in the disease 
course and include pitting thickening, tenderness and 
dumpling of the palmar skin. Skin pitting is a result of the 
involvement and retraction of the vertical Grapow bands. 
Typically the patient presents with slowly progressive skin 
symptoms of the palmar surface or, less frequently, of the 
digits. Palmar nodules, or cords maybe present and the 
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  Dupuytren’s nodules are the result of fibroblast 
proliferation and excessive collagen production and arise 
from the superficial bands of the palmodigital fascia. The 
nodules which are fixed to the skin and the deep fascia are 
firm and may be tender. They are pathognomonic [36, 49] 
and may appear in the palm or digits. Yet soft tissue tumors 
of the palm and digits may be confused with Dupuytren’s 
disease [47] and must be excluded from the diagnosis, 
especially in younger patients and those without known risk 
factors. Typically the nodules are replaced by the disease 
cords [48] following a spontaneous regression. 
  The cords blend with nodules initially and attach the 
overlying skin by diseased vertical fascial bands [49]. They 
develop usually distal to nodule in the palmar, palmodigital 
or digital area. Contractions of the cords, over the course of 
months to several years, leads eventually to fixed contracture 
of the metacarpophalngeal joint or the interphalangeal joints. 
In addition to progressive reduction of the range of motion, 
nerve compression and vascular displacement may occur as a 
result of the increasing severity of these contractures. 
  A simple grading system to assess the involvement of 
Dupuytren’s disease and to monitor progression was 
described by Tubiana et al. in 1968 and although having 
multiple modifications proposed over the years still remains 
a simple clinical grading system to use as shown in Table 1 
[50]. In this grading system the total flexion deformity of 
each finger is documented and scored between 0-4 as the 
table below shows. The addition of a P for Palmar and D for 
Digit describes where the deformity has mainly arisen from 
and assists in surgical planning. 
Table 1.  Grading System for Dupuytren’s Disease [50] 
 
N  Palmar Nodule without Presence of Contracture 
0 No  lesion 
1  TFD between 0° and 45° 
2  TFD between 45° and 90° 
3  TFD between 90° and 135° 
4  TFD greater than 135° 
 
  Dupuytren's diathesis was first described by Heuston and 
implicates more aggressive expression of the disease in 
patient with certain risk factors [51]. This is an important 
concept to consider as managing a patients expectations and 
long term prognosis has a significant impact on the 
morbidity of the disease. Risk factors that are considered to 
predict a more aggressive course and higher recurrence rate 
after surgery include; white race, early age of onset – 
younger than 40 years, strong family history, bilateral 
involvement and ectopic manifestation. Ectopic 
manifestations are most commonly encountered on the 
dorsum of the hand and includes knuckle pads and Garrods 
nodes located at the proximal interphalangeal joints [52]. 
Knuckle pads are present in 44-54% of the patients and most 
commonly affect the second finger [47, 48]. The prevalence 
of other ectopic manifestations is higher in the presence of 
knuckle pads [53]. These ectopic manifestations include 
plantar fibromatosis which is seen in 6-31% of the patients 
[48]. The condition known as Lederhose disease is usually 
asymptomatic and unlike to cause contracture [54]. Penile 
fibromatosis or Peyronie disease is caused by the 
development of fibrous plaques within the penile connective 
tissue and results in pain and deformity of the penis. The 
condition is encountered in 2-8% of Dupuytren cases [48, 
55]. 
NONOPERATIVE MANAGEMENT 
  Several agents and modalities have been suggested for 
the treatment of Dupuytren's contracture. Vitamin E, 
gamma-interferon, dimethylsulfoxide and splinting, have 
been shown to be ineffective [56]. Local steroids injection 
has also been performed with limited success [57]. 
Radiotherapy has been shown to stabilize progression of the 
disease in several studies, and might be used in the early 
stages to prevent progression [58]. In their in vitro study, 
Rayan  et al. found that Verapmil and Nifidipine inhibits 
myofibroblast contraction, and thus may be useful in the 
early stages of the disease [28]. The use of 5-Fluorouracil 
has been found, in vitro, to cause a dose-dependent selective 
and specific decrease in collagen production by inhibition of 
fibroblast proliferation and myofibroblast differentiation 
[59]. The authors concluded that the clinical implication is 
that 5-fluorouracil could possibly reduce the recurrence of 
Dupuytren's disease in the hand. 
  One of the newest ideas for nonoperative treatments is 
with the use of an enzymatic fasciotomy by Clostridium 
histolyticum collegenase injection. This was approved by the 
US Food and Drug Administration (FDA) in February 2010. 
In a phase III trial conducted by Badalamente et al, 
collegenase injection was shown to be safe and effective, 
with a low recurrence rate. Adverse effects included pain at 
the injection site, minimal hematoma and swelling [60]. 
Recently Hurst et al. reported the use of Clostridium 
histolyticum collegenase injection for the treatment of 
patients with contracture of at least 20º in a randomized 
controlled double blind study [61]. A significant 
improvement in the contractures and the range of movement 
was shown with more than 90% correction in the MCP joint, 
66% correction of the PIP joint, and low recurrence rates. 
The results of these studies are very promising and may lead 
toward a significant change in our approach to Dupuytren's 
disease in favor of nonoperative treatment. 
SURGICAL TREATMENT 
  Despite the advanced understanding of the pathogenesis, 
and the recently reported promising results of non-operative 
treatment modalities, surgical intervention remains the 
therapy of choice for advanced  stages of Dupuytren's 
contracture. 
  Generally nodules and cords do not cause pain or 
functional impairment, therefore surgical treatment is not 
indicated if a contracture is not present. The presence of a 
cord accompanied by a metacarpophalngeal flexion 
contracture of more than 30º, or a proximal interphalangeal 
joint contracture of any degree is accepted indications for 
surgical intervention [49, 62]. Another indication for surgery 
is a finger with a neurovascular deficit. 
  The results of surgery for contracture of the 
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correction of the proximal interphalangeal joints [63]. As a 
general role the incisions may be primary closed or left open 
for secondary healing. Both techniques are reported with 
good results [64]. Full thickness grafts and rotational flaps 
may also be used when primary closure is not possible. 
 Fasciotomy:  Limited open fasciotomy or percutaneous 
needle fasciotomy may be performed. In both procedures the 
fascia is divided without excision. Fasciotomy is the least 
extensive procedure among those used for the treatment of 
Dupuytren's disease. Rodrigo et al. reported that 43% of 
patient underwent fasciotomy required repeated surgery [65]. 
In a more recent study repeated surgery was required in 34% 
of the cases [66]. The high recurrence rate has resulted in 
this procedure being limited to the use in elderly debilitated 
patients in whom more extensive procedures are 
contraindicated [66, 67], however the temporary relief that 
can be achieved by a percutaneous release within an 
outpatient setting cannot be ignored. Neurovascular and 
flexor tendon injury are the main complications of the 
procedure. 
 Selective  fasciectomy: In this procedure the grossly 
involved fascia is excised. As the disease extend beyond the 
limits of the macroscopically involved tissue, all diseased 
tissue may not be removed. However, good results and a low 
recurrence rate were reported [68]. Selective fasciectomy is a 
limited procedure with low complication rates and 
acceptable results; therefore, selective fasciectomy is very 
common procedure used for the treatment of Dupuytren's 
disease 
 Radical  fasciectomy:  This procedure was described by 
McIndoe and Beare [69], and included complete removal of 
the palmar and digits fascia. It was originally performed by 
transverse palmar incision with the addition of digital z 
plasties when necessary. Although satisfactory results were 
reported by McIndoe, later studies have demonstrated similar 
functional outcome [69] and recurrence rate [66] compared 
with selective fasciectomy [68, 70]. Radical fasciectomy is 
not commonly performed, because of the increased 
morbidity and complication rates. Common complications 
include hematoma, joint stiffness, and delayed healing. 
 Segmental  aponeurectomy:  Entails partial removal of 
one or more segments of diseased fascia through multiple 
small incisions. Small curved insertions are located over the 
cord and planned so that they can enable nodule excision. 
The goal is to create a discontinuity in the retracted 
aponeurotic band without wide dissection of the fascia itself, 
and thus eliminate the tension in the retracted cord Good 
results of the procedure with acceptable recurrence rate were 
reported [70]. 
 Dermofasciectomy: The risk of recurrence following 
fasciectomy was significantly reduced when excision of the 
skin overlying the cord and skin grafting was added [71]. 
Hueston suggested that dermis and the underlying layers 
provide a source for the disease recurrence [72]. In 
dermofasciectomy the diseased fascia and the overlying skin 
are resected. Early studies reported prevention of recurrence 
especially when the procedure was accompanied by the use 
of full thickness grafts [73]. However, more recent studies 
have reported a low rate of recurrence [74]. 
Dermofasciectomy combined with skin grafting is usually 
used for the treatment of recurrent disease. 
 Amputation: In the setting of Dupuytren's disease 
amputation is carried out at the level of the proximal 
interphalangeal joint. It is indicated in cases of severe 
uncorrectable contracture or neurovascular damage. In a 
recent report finger amputation due to Dupuytren's disease 
was found to be the predominant reason for elective finger 
amputation in adults. Among the procedures performed for 
the treatment of Dupuytren's disease 2% were elective 
amputations [75]. 
  As a general rule following surgical treatment, the hand 
is dressed and splinted with the metacarpophalngeal joints in 
a position of function (45-70° flexion) and the proximal 
interphalangeal joints extended [74, 76]. Physiotherapy is 
commenced immediately to avoid stiffness. 
THE ROLE OF STEM CELLS 
  The source of abnormal cells leading to Dupuytren's 
disease formation remains underexplored. In addition to 
fascia, palmar skin and fat-derived cells may be a potential 
source of cells causing Dupuytren's disease. A study aimed 
to profile haematopoietic and mesenchymal stem cells in 
different Dupuytren's disease tissue components compared 
with tissue removed at carpal tunnel surgery as control [77]. 
Fluorescence-activated cell sorting (FACS) and quantitative 
real-time polymerase chain reaction (QRT-PCR) analysis 
identified the highest RNA expression and number of cells 
positive for adipocyte stem cell markers (CD13 and CD29) 
in the Dupuytren's disease nodule. CD34 RNA was 
overexpressed, and a higher percentage of these cells were 
present in Dupuytren's disease skin compared with carpal 
tunnel skin. Each structural component of Dupuytren's 
disease had distinct stem cell populations. These findings 
support the hypothesis that Dupuytren's disease may result 
from mesenchymal progenitor cell expansion. 
COMPLICATIONS 
  Intraoperative and postoperative complications of the 
corrective surgical procedures are common. The reported 
rate of complications for surgical treatment of Dupuytren's 
disease ranges from 6% to 46%. Greater initial deformity 
and more severe disease were found to increase the 
complication rate [63, 78]. Recurrence, one of the most 
common and frustrating complication, occurs in 2-60% of 
cases [63, 74]. This wide variety is explained by the different 
definition of recurrence used by different authors. As noticed 
previously, dermofaciectomy seems to result in lower rates 
of recurrence. The altered anatomy which includes 
displacement of the neurovascular bundle and the need of 
dissecting it along the cord increases the risk for 
neurovascular injury. However this risk may be reduced by 
applying a meticulous technique. Denkler reviewed the 
literature pertaining to surgical complications in Dupuytren’s 
disease and noted a major complication rate of 15.7% with 
injury to the digital nerve occurring in 3.4% of cases and 
vascular damage during fasciectomy occurring in 2% of 
cases [79]. Infection is a common wound complication in 
fasciectomy affecting 3.9% of patients. The presence of a 
hematoma correlate with higher infection rates, efforts 
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homeostasis. Another wound complication includes flap 
necrosis and graft failure. Complex regional pain syndrome 
is a serious and common complication affecting 4.5% of 
cases following fasciectomy [79] and is far more common in 
women. It should be noted that the rate of complications 
dramatically rose in those who underwent further surgery for 
recurrent contractures. 
SUMMARY 
  Dupuytren disease is a disabling disorder of the hand of 
unknown cause. In the last decade several molecular 
mechanisms have been identified which play a role in the 
disease pathogenesis. Currently surgical treatment is the 
most widely offered solution to Dupuytren’s as it offers a 
functional improvement for most of the patients. However, it 
results in high rates of complications and recurrences. 
Comprehensive understanding of the complex anatomical 
nature of the disease is crucial for applying appropriate 
surgical treatment. Enzymatic fasciotomy using Clostridium 
histolyticum collegenase is a new local treatment modality 
with an excellent short term result. Further studies are 
needed for the evaluation of the long term result, 
complications and recurrence rate, as well as studies to better 
ascertain the etiology and determine the role of stem cell 
therapy. 
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